Genetic/JJ
Analysis/NN
of/IN
SCN5A/NN
in/IN
Korean/JJ
Patients/NNS
Associated/VBN
with/IN
Atrioventricular/JJ
Conduction/NN
Block/NN
./.
====================
Recent/JJ
several/JJ
studies/NNS
have/VBP
shown/VBN
that/IN
the/DT
genetic/JJ
variation/NN
of/IN
SCN5A/NN
is/VBZ
related/JJ
with/IN
atrioventricular/JJ
conduction/NN
block/VBP
(/(
AVB/NN
)/)
;/:
no/DT
study/NN
has/VBZ
yet/RB
been/VBN
published/VBN
in/IN
Koreans/NNS
./.
====================
Therefore/RB
,/,
to/TO
determine/VB
the/DT
AVB-associated/JJ
genetic/JJ
variation/NN
in/IN
Korean/JJ
patients/NNS
,/,
we/PRP
investigated/VBD
the/DT
genetic/JJ
variation/NN
of/IN
SCN5A/NN
in/IN
Korean/JJ
patients/NNS
with/IN
AVB/NN
and/CC
compared/VBD
with/IN
normal/JJ
control/JJ
subjects/NNS
./.
====================
We/PRP
enrolled/VBD
113/CD
patients/NNS
with/IN
AVB/NN
and/CC
80/CD
normal/JJ
controls/NNS
with/IN
no/DT
cardiac/JJ
symptoms/NNS
./.
====================
DNA/NN
was/VBD
isolated/VBN
from/IN
the/DT
peripheral/JJ
blood/NN
,/,
and/CC
all/DT
exons/NNS
(/(
exon/NN
2-exon/JJ
28/CD
)/)
except/IN
the/DT
untranslated/JJ
region/NN
and/CC
exon-intron/NN
boundaries/NNS
of/IN
the/DT
SCN5A/NN
gene/NN
were/VBD
amplified/VBN
by/IN
multiplex/JJ
PCR/NN
and/CC
directly/RB
sequenced/VBN
using/VBG
an/DT
ABI/NN
PRISM/NN
3100/CD
Genetic/JJ
Analyzer/NN
./.
====================
When/WRB
a/DT
variation/NN
was/VBD
discovered/VBN
in/IN
genomic/JJ
DNA/NN
from/IN
AVB/NN
patients/NNS
,/,
we/PRP
confirmed/VBD
whether/IN
the/DT
same/JJ
variation/NN
existed/VBD
in/IN
the/DT
control/NN
genomic/JJ
DNA/NN
./.
====================
In/IN
the/DT
present/JJ
study/NN
,/,
a/DT
total/JJ
of/IN
7/CD
genetic/JJ
variations/NNS
were/VBD
detected/VBN
in/IN
113/CD
AVB/NN
patients/NNS
./.
====================
Of/IN
the/DT
7/CD
variations/NNS
,/,
5/CD
(/(
G87A-A29A/NN
,/,
intervening/VBG
sequence/NN
9-3C/NN
>/JJR
A/DT
,/,
A1673G-H558R/NN
,/,
G3578A-R1193Q/NN
,/,
and/CC
T5457C-D1819D/NN
)/)
have/VBP
been/VBN
reported/VBN
in/IN
previous/JJ
studies/NNS
,/,
and/CC
2/CD
(/(
C48G-F16L/NN
and/CC
G3048A-T1016T/NN
)/)
were/VBD
novel/JJ
variations/NNS
that/IN
have/VBP
not/RB
been/VBN
reported/VBN
./.
====================
The/DT
2/CD
newly/RB
discovered/VBN
variations/NNS
were/VBD
not/RB
found/VBN
in/IN
the/DT
80/CD
normal/JJ
controls/NNS
./.
====================
In/IN
addition/NN
,/,
G298S/NN
,/,
G514C/NN
,/,
P1008S/NN
,/,
G1406R/NN
,/,
and/CC
D1595N/NN
,/,
identified/VBD
in/IN
other/JJ
ethnic/JJ
populations/NNS
,/,
were/VBD
not/RB
detected/VBN
in/IN
this/DT
study/NN
./.
====================
We/PRP
found/VBD
2/CD
novel/JJ
genetic/JJ
variations/NNS
in/IN
the/DT
SCN5A/NN
gene/NN
in/IN
Korean/JJ
patients/NNS
with/IN
AVB/NN
./.
====================
However/RB
,/,
further/RBR
functional/JJ
study/NN
might/MD
be/VB
needed/VBN
./.
====================
The/DT
SCN5A/NN
gene/NN
,/,
encoding/VBG
a/DT
voltage-gated/JJ
Na+/JJ
channel/NN
,/,
is/VBZ
predominately/RB
expressed/VBN
in/IN
the/DT
heart/NN
,/,
where/WRB
it/PRP
has/VBZ
a/DT
key/JJ
role/NN
in/IN
the/DT
generation/NN
and/CC
propagation/NN
of/IN
the/DT
cardiac/JJ
impulse/VBP
[/(
1/CD
]/)
./.
====================
Voltage-gated/JJ
Na+/JJ
channels/NNS
are/VBP
transmembrane/JJ
proteins/NNS
that/WDT
produce/VBP
the/DT
fast/JJ
inward/IN
Na+/JJ
current/JJ
responsible/JJ
for/IN
the/DT
depolarization/NN
phase/NN
of/IN
the/DT
cardiac/JJ
action/NN
potential/JJ
./.
====================
Inherited/JJ
variations/NNS
in/IN
SCN5A/NN
,/,
the/DT
gene/NN
encoding/VBG
the/DT
pore-forming/NN
α-subunit/NN
of/IN
the/DT
cardiac-type/JJ
Na+/JJ
channel/NN
(/(
Nav1.5/NN
)/)
,/,
result/NN
in/IN
a/DT
spectrum/NN
of/IN
disease/NN
entities/VBZ
,/,
termed/VBN
Na+/JJ
channelopathies/NNS
./.
====================
In/IN
many/JJ
previous/JJ
studies/NNS
,/,
lots/NNS
of/IN
variations/NNS
of/IN
the/DT
SCN5A/NN
gene/NN
have/VBP
been/VBN
observed/VBN
in/IN
various/JJ
cardiac/JJ
diseases/NNS
,/,
such/JJ
as/IN
long-QT/JJ
syndrome/NN
(/(
LQT/NN
)/)
,/,
Brugada/NN
syndrome/NN
(/(
Brs/NNS
)/)
,/,
progressive/JJ
cardiac/JJ
conduction/NN
defect/NN
,/,
atrial/JJ
fibrillation/NN
(/(
AF/NN
)/)
,/,
dilated/VBD
cardiomyopathy/JJ
,/,
and/CC
overlapping/VBG
syndromes/NNS
[/(
2/CD
,/,
3/CD
]/)
./.
====================
Recently/RB
,/,
cardiac/JJ
conduction/NN
system/NN
disease/NN
,/,
manifesting/VBG
as/IN
slower/JJR
intramyocardial/JJ
conduction/NN
and/CC
,/,
in/IN
some/DT
cases/NNS
,/,
atrioventricular/JJ
conduction/NN
block/VBP
(/(
AVB/NN
)/)
,/,
has/VBZ
been/VBN
related/JJ
to/TO
SCN5A/NN
mutation/NN
[/(
4/CD
]/)
./.
====================
Familial/JJ
AVB/NN
,/,
characterized/VBN
by/IN
progressive/JJ
``/NN
degree/NN
of/IN
block/VBP
''/JJ
in/IN
association/NN
with/IN
variable/JJ
apparent/JJ
``/NN
site/NN
of/IN
block/VBP
,/,
''/NNP
may/MD
be/VB
transmitted/VBN
as/IN
an/DT
autosomal/JJ
dominant/JJ
trait/VBP
./.
====================
Two/CD
genetically/RB
distinct/JJ
forms/NNS
of/IN
AVB/NN
have/VBP
been/VBN
identified/VBN
[/(
5/CD
]/)
./.
====================
Brink/NN
et/FW
al/JJ
./.
====================
[/(
6/CD
]/)
established/VBN
a/DT
genetic/JJ
link/NN
between/IN
AVB/NN
and/CC
a/DT
genetic/JJ
locus/NN
at/IN
chromosome/NN
19q13/NN
,/,
and/CC
Schott/NN
et/FW
al/JJ
./.
====================
[/(
4/CD
]/)
mapped/VBD
AVB/NN
to/TO
chromosome/NN
3p21/NN
./.
====================
Such/JJ
genetic/JJ
variations/NNS
in/IN
AVB/NN
patients/NNS
have/VBP
been/VBN
widely/RB
studied/VBN
in/IN
Caucasians/NNS
,/,
Han/JJ
Chinese/JJ
,/,
and/CC
Japanese/JJ
,/,
but/CC
no/DT
study/NN
has/VBZ
yet/RB
been/VBN
published/VBN
in/IN
Koreans/NNS
as/IN
far/RB
we/PRP
know/VBP
./.
====================
Therefore/RB
,/,
we/PRP
carried/VBD
out/RP
a/DT
complete/JJ
sequencing/NN
of/IN
coding/VBG
regions/NNS
of/IN
the/DT
SCN5A/NN
gene/NN
,/,
except/IN
the/DT
untranslated/JJ
region/NN
,/,
in/IN
Korean/JJ
AVB/NN
patients/NNS
to/TO
investigate/VB
the/DT
SCN5A/NN
variations/NNS
associated/VBN
with/IN
AVB/NN
and/CC
compared/VBD
them/PRP
with/IN
normal/JJ
control/JJ
subjects/NNS
./.
====================
This/DT
is/VBZ
the/DT
first/JJ
study/NN
of/IN
SCN5A/NN
genetic/JJ
variations/NNS
that/IN
examined/VBN
all/DT
coding/VBG
regions/NNS
in/IN
Korean/JJ
patients/NNS
with/IN
AVB/NN
./.
====================
Patient/JJ
enrollment/JJ
====================
We/PRP
enrolled/VBD
113/CD
Korean/NN
AVB/NN
patients/NNS
who/WP
were/VBD
diagnosed/VBN
with/IN
electrocardiograms/NNS
and/CC
who/WP
had/VBD
inserted/VBN
permanent/JJ
pacemakers/NNS
and/CC
80/CD
normal/JJ
controls/NNS
with/IN
no/DT
cardiac/JJ
symptoms/NNS
./.
====================
All/DT
patients/NNS
and/CC
control/NN
subjects/NNS
were/VBD
recruited/VBN
from/IN
four/CD
medical/JJ
centers/NNS
-/:
Keimyung/NN
University/NN
,/,
Yeungnam/JJ
University/NN
,/,
Catholic/JJ
University/NN
,/,
and/CC
Fatima/NN
Hospital/JJ
(/(
Daegu/NNP
,/,
Korea/NN
)/)
-/:
from/IN
August/NNP
2009/CD
to/TO
September/NN
2011/CD
./.
====================
This/DT
study/NN
was/VBD
approved/VBN
by/IN
the/DT
ethical/JJ
committee/VBP
at/IN
each/DT
hospital/JJ
;/:
consent/JJ
was/VBD
obtained/VBN
from/IN
all/DT
individuals/NNS
before/IN
enrollment/JJ
into/IN
the/DT
study/NN
./.
====================
DNA/NN
extraction/NN
====================
In/IN
this/DT
study/NN
,/,
peripheral/JJ
blood/NN
was/VBD
collected/VBN
into/IN
ethylenediamine/NN
tetraacetic/JJ
acid-containing/VBG
tubes/NNS
,/,
and/CC
genomic/JJ
deoxyribonucleic/JJ
acid/NN
(/(
DNA/NN
)/)
was/VBD
extracted/VBN
from/IN
whole/JJ
blood/NN
samples/NNS
using/VBG
the/DT
QIAamp/NN
DNA/NN
blood/NN
mini/NNS
kit/NN
(/(
Qiagen/NN
,/,
GmbH/JJ
,/,
Hilden/JJ
,/,
Germany/NNP
)/)
./.
====================
DNA/NN
concentration/NN
was/VBD
determined/VBN
using/VBG
a/DT
NanoDrop/JJ
ND1000/CD
spectrophotometer/NN
(/(
Thermo/DT
Fisher/RB
Scientific/JJ
Inc./NNP
,/,
Wilmington/JJ
,/,
DE/NN
,/,
USA/NNP
)/)
,/,
and/CC
purity/NN
of/IN
the/DT
DNA/NN
was/VBD
assessed/VBN
based/VBN
on/IN
the/DT
260/280/CD
nm/NN
absorbance/NN
ratio/NN
./.
====================
Multiplex/JJ
polymerase/NN
chain/NN
reaction/NN
(/(
PCR/NN
)/)
and/CC
sequence/NN
analysis/NN
====================
The/DT
SCN5A/NN
gene/NN
is/VBZ
located/JJ
on/IN
human/JJ
chromosome/NN
3p21/NN
,/,
and/CC
the/DT
gene/NN
consists/VBZ
of/IN
28/CD
exons/NNS
(/(
Fig/NN
./.
====================
1/CD
)/)
and/CC
encodes/VBZ
a/DT
protein/NN
of/IN
2,016/CD
amino/NN
acids/NNS
with/IN
a/DT
molecular/JJ
mass/NN
of/IN
227/CD
kDa/NN
[/(
7/CD
]/)
./.
====================
Entire/NN
coding/VBG
regions/NNS
,/,
including/VBG
exon-intron/NN
boundaries/NNS
of/IN
the/DT
SCN5A/NN
gene/NN
,/,
were/VBD
amplified/VBN
by/IN
multiplex/JJ
PCR-based/JJ
direct/JJ
sequencing/NN
./.
====================
The/DT
primers/NNS
for/IN
PCR/NN
amplification/NN
were/VBD
designed/VBN
based/VBN
on/IN
the/DT
GenBank/NN
reference/VBP
sequence/NN
;/:
primers/NNS
are/VBP
shown/VBN
in/IN
Table/JJ
1/CD
./.
====================
PCR/NN
conditions/NNS
were/VBD
as/IN
follows/VBZ
:/:
an/DT
initial/JJ
denaturation/NN
at/IN
95℃/CD
for/IN
15/CD
min/NN
;/:
and/CC
denaturation/NN
at/IN
94℃/CD
for/IN
30/CD
s/NNS
,/,
annealing/VBG
at/IN
68-70℃/CD
for/IN
30-60/CD
s/NNS
,/,
and/CC
extension/NN
at/IN
72℃/CD
for/IN
60-90/CD
s/NNS
,/,
repeated/VBN
for/IN
30/CD
cycles/NNS
(/(
Table/JJ
1/CD
)/)
./.
====================
After/IN
multiplex/JJ
PCR/NN
,/,
the/DT
reaction/NN
mixture/NN
was/VBD
electrophoresed/VBN
in/IN
a/DT
2/CD
%/NN
agarose/IN
gel/NN
and/CC
stained/VBD
with/IN
ethidium/NN
bromide/NN
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
Then/RB
,/,
amplified/VBN
PCR/NN
products/NNS
were/VBD
purified/VBN
using/VBG
the/DT
QIAquick/NN
PCR/NN
purification/NN
kit/NN
(/(
Qiagen/NN
)/)
and/CC
directly/RB
sequenced/VBN
using/VBG
the/DT
BigDye/NN
Terminator/NN
ver/RB
3.1/CD
cycle/NN
sequencing/NN
kit/NN
on/IN
an/DT
ABI/NN
PRISM/NN
3100/CD
Genetic/JJ
Analyzer/NN
(/(
Applied/VBN
Biosystems/NNS
,/,
Foster/NN
City/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
./.
====================
Sequencing/NN
results/NNS
were/VBD
compared/VBN
with/IN
the/DT
reference/NN
sequences/NNS
(/(
SCN5A/NM_198056.2/ENSG00000183873/ENST00000333535/NN
)/)
using/VBG
the/DT
alignment/NN
program/NN
BLAST/NN
2.0/CD
of/IN
NCBI/NN
,/,
and/CC
we/PRP
determined/VBD
the/DT
portion/NN
of/IN
variation/NN
that/IN
occurred/VBD
./.
====================
When/WRB
a/DT
variation/NN
was/VBD
discovered/VBN
in/IN
genomic/JJ
DNA/NN
from/IN
patients/NNS
,/,
we/PRP
confirmed/VBD
whether/IN
the/DT
same/JJ
variation/NN
existed/VBD
in/IN
the/DT
control/NN
genomic/JJ
DNA/NN
./.
====================
Statistical/JJ
analysis/NN
====================
p-values/NNS
and/CC
odds/NNS
ratios/NNS
with/IN
95/CD
%/NN
confidence/NN
intervals/NNS
for/IN
each/DT
genotype/NN
and/CC
allele/NN
were/VBD
evaluated/VBN
by/IN
χ2/NN
analysis/NN
./.
====================
A/DT
p-value/JJ
of/IN
</JJR
0.05/CD
was/VBD
considered/VBN
to/TO
indicate/VB
a/DT
statistically/RB
significant/JJ
difference/NN
between/IN
AVB/NN
patients/NNS
and/CC
normal/JJ
controls/NNS
of/IN
the/DT
study/NN
./.
====================
In/IN
the/DT
present/JJ
study/NN
,/,
we/PRP
sequenced/VBD
all/DT
translated/VBN
exons/NNS
and/CC
exon-intron/NN
boundaries/NNS
of/IN
the/DT
SCN5A/NN
gene/NN
from/IN
113/CD
Korean/NN
AVB/NN
patients/NNS
./.
====================
As/IN
a/DT
result/JJ
,/,
we/PRP
identified/VBD
7/CD
genetic/JJ
variations/NNS
(/(
of/IN
these/DT
,/,
5/CD
were/VBD
known/VBN
variations/NNS
and/CC
2/CD
were/VBD
novel/JJ
variations/NNS
)/)
,/,
consisting/VBG
of/IN
3/CD
synonymous/JJ
(/(
G87A-A29A/NNP
,/,
G3048A-T1016T/JJ
,/,
and/CC
T5457C-D1819D/NN
)/)
,/,
3/CD
non-synonymous/JJ
(/(
C48G-F16L/NN
,/,
A1673G-H558R/NN
,/,
and/CC
G3578A-R1193Q/NN
)/)
,/,
and/CC
1/CD
splicing/NN
donor/CC
site/NN
of/IN
the/DT
intron/NN
9-exon/JJ
10/CD
boundary/RB
(/(
intervening/VBG
sequence/NN
[/(
IVS/NN
]/)
9-3C/NN
>/JJR
A/DT
)/)
(/(
Table/JJ
2/CD
)/)
./.
====================
The/DT
examples/NNS
of/IN
the/DT
sequencing/NN
result/NN
are/VBP
shown/VBN
in/IN
Fig/NN
./.
====================
3/CD
./.
====================
Among/IN
the/DT
7/CD
genetic/JJ
variations/NNS
,/,
2/CD
single/JJ
nucleotide/NN
polymorphisms/NNS
(/(
SNPs/NNS
)/)
have/VBP
been/VBN
reported/VBN
by/IN
American/NN
and/CC
Japanese/JJ
researchers/NNS
:/:
non-synonymous/JJ
SNP/NN
in/IN
exon/NN
12/CD
(/(
rs1805124/CD
,/,
A1673G-H558R/NN
)/)
and/CC
synonymous/JJ
SNP/NN
in/IN
exon/NN
28/CD
(/(
rs1805126/NN
,/,
C5457T-D1819D/NN
)/)
./.
====================
A1673G-H558R/NN
was/VBD
identified/VBN
in/IN
18/CD
%/NN
of/IN
the/DT
American/NN
populations/NNS
(/(
n/NN
=/JJ
71/CD
)/)
and/CC
8/CD
%/NN
of/IN
the/DT
Japanese/JJ
populations/NNS
(/(
n/NN
=/JJ
100/CD
)/)
[/(
8/CD
,/,
9/CD
]/)
,/,
and/CC
C5457T-D1819D/NN
was/VBD
observed/VBN
in/IN
12.3/CD
%/NN
of/IN
the/DT
American/NN
populations/NNS
(/(
n/NN
=/JJ
130/CD
)/)
and/CC
46/CD
%/NN
of/IN
the/DT
Japanese/JJ
populations/NNS
(/(
n/NN
=/JJ
100/CD
)/)
[/(
9/CD
,/,
10/CD
]/)
./.
====================
We/PRP
also/RB
discovered/VBD
a/DT
synonymous/JJ
SNP/NN
(/(
rs6599230/CD
:/:
G87A-A29A/NN
,/,
in/IN
exon/NN
2/CD
)/)
and/CC
non-synonymous/JJ
SNP/NN
(/(
rs41261344/NN
,/,
G3578A-R1193Q/NN
,/,
in/IN
exon/NN
20/CD
)/)
that/WDT
are/VBP
very/RB
common/JJ
polymorphisms/NNS
in/IN
the/DT
Han/JJ
Chinese/JJ
population/NN
./.
====================
In/IN
addition/NN
,/,
we/PRP
identified/VBD
2/CD
novel/JJ
variations/NNS
that/IN
have/VBP
not/RB
been/VBN
previously/RB
reported/VBD
./.
====================
One/CD
of/IN
these/DT
variations/NNS
was/VBD
heterozygous/JJ
synonymous/JJ
(/(
G3048A-T1016T/NN
)/)
,/,
and/CC
the/DT
other/JJ
was/VBD
heterozygous/JJ
non-synonymous/JJ
(/(
C48G-F16L/NN
)/)
./.
====================
The/DT
genotype/NN
and/CC
allele/NN
frequencies/NNS
of/IN
the/DT
identified/VBN
genetic/JJ
variations/NNS
are/VBP
summarized/VBN
in/IN
Table/JJ
2/CD
./.
====================
There/EX
were/VBD
significant/JJ
differences/NNS
in/IN
the/DT
allele/NN
frequencies/NNS
of/IN
A1673G-H558R/NN
and/CC
G3048A/NN
(/(
T1016T/NN
)/)
between/IN
the/DT
two/CD
groups/NNS
(/(
p/NN
</JJR
0.05/CD
)/)
./.
====================
There/EX
were/VBD
no/DT
statistically/RB
significant/JJ
differences/NNS
in/IN
allele/NN
frequencies/NNS
of/IN
the/DT
other/JJ
genetic/JJ
variations/NNS
between/IN
the/DT
two/CD
groups/NNS
(/(
all/DT
p/NN
>/JJR
0.05/CD
)/)
./.
====================
However/RB
,/,
G298S/NN
[/(
11/CD
]/)
,/,
G514C/NNP
[/(
12/CD
]/)
,/,
P1008S/NN
[/(
13/CD
]/)
,/,
G1406R/NN
[/(
14/CD
]/)
,/,
and/CC
D1595N/NN
[/(
11/CD
]/)
,/,
identified/VBD
in/IN
other/JJ
ethnic/JJ
populations/NNS
,/,
were/VBD
not/RB
detected/VBN
,/,
and/CC
A3075T-E1025D/NN
and/CC
T4847A-F1616Y/NN
,/,
discovered/VBN
in/IN
105/CD
Korean/JJ
sick/JJ
sinus/JJ
syndrome/NN
patients/NNS
in/IN
our/PRP$
previous/JJ
study/NN
,/,
were/VBD
also/RB
not/RB
detected/VBN
in/IN
this/DT
study/NN
./.
====================
Next/RB
,/,
to/TO
compare/VB
with/IN
normal/JJ
controls/NNS
,/,
we/PRP
analyzed/VBD
normal/JJ
samples/NNS
by/IN
the/DT
same/JJ
methods/NNS
whether/IN
the/DT
same/JJ
variations/NNS
existed/VBD
in/IN
their/PRP$
genes/NNS
./.
====================
Just/RB
as/IN
in/IN
the/DT
patient/NN
group/NN
,/,
4/CD
SNPs/NNS
(/(
rs6599230/CD
,/,
G87A-A29A/NNP
;/:
rs41312434/RB
,/,
IVS9-3C/NN
>/JJR
A/DT
;/:
rs1805124/RB
,/,
A1673G-H558R/NN
;/:
rs1805126/RB
,/,
C5457T-D1819D/NN
)/)
were/VBD
detected/VBN
in/IN
the/DT
normal/JJ
control/JJ
group/NN
,/,
but/CC
1/CD
non-synonymous/JJ
SNP/NN
(/(
rs41261344/NN
,/,
G3578A-R1193Q/NNP
)/)
and/CC
2/CD
novel/JJ
variations/NNS
(/(
C48G-F16L/NN
and/CC
G3048A-T1016T/NN
)/)
were/VBD
not/RB
detected/VBN
in/IN
the/DT
normal/JJ
control/JJ
group/NN
./.
====================
This/DT
is/VBZ
the/DT
first/JJ
case/NN
report/VBP
with/IN
genetic/JJ
variations/NNS
of/IN
SCN5A/NN
in/IN
Korean/JJ
patients/NNS
with/IN
AVB/NN
./.
====================
To/TO
date/NN
,/,
a/DT
number/NN
of/IN
SCN5A/NN
variations/NNS
associated/VBN
with/IN
various/JJ
cardiac/JJ
diseases/NNS
,/,
such/JJ
as/IN
LQT/JJ
,/,
Brs/NNS
,/,
progressive/JJ
cardiac/JJ
conduction/NN
defect/NN
,/,
AF/NN
,/,
and/CC
overlapping/VBG
syndromes/NNS
,/,
have/VBP
been/VBN
reported/VBN
./.
====================
Although/IN
SCN5A/NN
genetic/JJ
variations/NNS
associated/VBN
with/IN
AVB/NN
have/VBP
been/VBN
well/RB
studied/VBN
in/IN
Caucasians/NNS
,/,
Han/JJ
Chinese/JJ
,/,
and/CC
Japanese/JJ
,/,
no/DT
study/NN
has/VBZ
yet/RB
been/VBN
published/VBN
in/IN
Koreans/NNS
as/IN
far/RB
we/PRP
know/VBP
./.
====================
In/IN
previous/JJ
studies/NNS
,/,
it/PRP
has/VBZ
been/VBN
shown/VBN
that/IN
in/IN
some/DT
cases/NNS
,/,
progressive/JJ
AVB/NN
has/VBZ
been/VBN
linked/VBN
to/TO
SCN5A/NN
gene/NN
variations/NNS
[/(
4/CD
]/)
./.
====================
Furthermore/RB
,/,
in/IN
our/PRP$
prior/JJ
study/NN
,/,
2/CD
novel/JJ
variations/NNS
were/VBD
detected/VBN
in/IN
Korean/JJ
sick/JJ
sinus/JJ
syndrome/NN
(/(
SSS/NN
)/)
patients/NNS
,/,
which/WDT
,/,
to/TO
our/PRP$
knowledge/NN
,/,
has/VBZ
not/RB
been/VBN
previously/RB
reported/VBD
in/IN
any/DT
ethnic/JJ
group/NN
./.
====================
The/DT
variations/NNS
could/MD
be/VB
significantly/RB
associated/VBN
with/IN
functional/JJ
effects/NNS
of/IN
the/DT
SCN5A/NN
gene/NN
./.
====================
Based/VBN
on/IN
these/DT
results/NNS
,/,
we/PRP
searched/VBD
for/IN
SCN5A/NN
genetic/JJ
variations/NNS
in/IN
Korean/JJ
AVB/NN
and/CC
compared/VBN
them/PRP
with/IN
those/DT
of/IN
control/JJ
subjects/NNS
./.
====================
The/DT
SCN5A/NN
gene/NN
consists/VBZ
of/IN
28/CD
exons/NNS
and/CC
encodes/VBZ
a/DT
protein/NN
of/IN
2016/CD
amino/NN
acids/NNS
with/IN
a/DT
molecular/JJ
mass/NN
of/IN
227/CD
kDa/NN
[/(
7/CD
]/)
./.
====================
In/IN
our/PRP$
patients/NNS
with/IN
AVB/NN
,/,
there/EX
were/VBD
7/CD
sites/NNS
of/IN
nucleotide/NN
change/NN
from/IN
exon/NN
2/CD
to/TO
exon/NN
28/CD
of/IN
the/DT
SCN5A/NN
gene/NN
./.
====================
Among/IN
of/IN
them/PRP
,/,
2/CD
sites/NNS
(/(
G87A-A29A/NNP
,/,
IVS9-3C/NN
>/JJR
A/DT
)/)
were/VBD
reported/VBN
as/IN
genetic/JJ
variations/NNS
in/IN
a/DT
Western/NN
study/NN
[/(
7/CD
]/)
,/,
and/CC
T5457C-D1819D/NN
has/VBZ
already/RB
been/VBN
reported/VBN
as/IN
a/DT
variation/NN
or/CC
polymorphism/NN
without/IN
functional/JJ
effects/NNS
on/IN
the/DT
channel/NN
in/IN
Asian/JJ
studies/NNS
[/(
7/CD
,/,
15/CD
,/,
16/CD
]/)
./.
====================
A1673G-H558R/NN
is/VBZ
located/JJ
in/IN
the/DT
Na+/JJ
channel/NN
I/NN
,/,
II/CD
interdomain/NN
linker/NN
,/,
and/CC
previous/JJ
functional/JJ
studies/NNS
have/VBP
shown/VBN
that/IN
the/DT
H558R-encoding/JJ
minor/JJ
allele/NN
can/MD
alter/VB
the/DT
phenotype/NN
of/IN
true/JJ
disease-causing/VBG
SCN5A/NN
mutations/NNS
[/(
17/CD
]/)
./.
====================
It/PRP
has/VBZ
been/VBN
suggested/VBN
that/IN
it/PRP
modulates/VBZ
Na+/JJ
channel/NN
functional/JJ
changes/NNS
caused/VBD
by/IN
other/JJ
variations/NNS
and/CC
plays/VBZ
a/DT
role/NN
in/IN
intragenic/JJ
complementation/NN
[/(
18/CD
,/,
19/CD
]/)
./.
====================
Previously/RB
,/,
the/DT
H558R/NN
G/NN
allele/NN
has/VBZ
been/VBN
associated/VBN
with/IN
occurrence/NN
of/IN
early-onset/JJ
AF/NN
and/CC
LQT/NN
interval/JJ
in/IN
healthy/JJ
populations/NNS
./.
====================
The/DT
H558R/NN
G/NN
allele/NN
frequency/NN
has/VBZ
been/VBN
reported/VBN
to/TO
be/VB
20.4-32/CD
%/NN
in/IN
the/DT
white/JJ
population/NN
,/,
29/CD
%/NN
in/IN
the/DT
black/JJ
population/NN
,/,
and/CC
10.4/CD
%/NN
in/IN
the/DT
Chinese/JJ
population/NN
./.
====================
In/IN
our/PRP$
study/NN
,/,
the/DT
G/NN
allele/NN
frequency/NN
of/IN
SCN5A/NN
mutation/NN
carriers/NNS
was/VBD
8/CD
%/NN
and/CC
13.1/CD
%/NN
in/IN
the/DT
normal/JJ
control/JJ
group/NN
./.
====================
G3578A-R1193Q/NN
,/,
which/WDT
can/MD
cause/VB
a/DT
gain/NN
of/IN
the/DT
sodium/NN
ion/NN
channel/NN
function/NN
and/CC
cause/VBP
LQT3/NN
and/CC
Brs/NNS
,/,
was/VBD
also/RB
found/VBD
./.
====================
It/PRP
has/VBZ
been/VBN
reported/VBN
that/IN
G3578A-R1193Q/NN
confers/VBZ
a/DT
risk/NN
of/IN
LQT3/NN
or/CC
Brs/NNS
in/IN
the/DT
general/JJ
population/NN
,/,
although/IN
it/PRP
seems/VBZ
to/TO
be/VB
a/DT
common/JJ
polymorphism/NN
in/IN
the/DT
Han/JJ
Chinese/JJ
population/NN
./.
====================
Electrophysiological/JJ
studies/NNS
showed/VBD
that/IN
R1193Q/NN
destabilizes/VBZ
inactivation/NN
gating/VBG
and/CC
generates/VBZ
a/DT
persistent/JJ
,/,
non-inactivating/JJ
current/JJ
,/,
which/WDT
results/VBZ
in/IN
a/DT
gain/NN
of/IN
the/DT
sodium/NN
channel/NN
function/NN
,/,
as/IN
in/IN
LQT3/NN
syndrome/NN
[/(
20/CD
,/,
21/CD
]/)
./.
====================
In/IN
addition/NN
to/TO
previously/RB
reported/VBD
variations/NNS
,/,
we/PRP
identified/VBD
2/CD
novel/JJ
variations/NNS
that/IN
were/VBD
not/RB
reported/VBN
in/IN
the/DT
case/NN
of/IN
Japanese/JJ
and/CC
Chinese/JJ
populations/NNS
./.
====================
One/CD
of/IN
these/DT
variations/NNS
was/VBD
heterozygous/JJ
non-synonymous/JJ
(/(
C48G-F16L/NN
)/)
,/,
and/CC
the/DT
other/JJ
was/VBD
heterozygous/JJ
synonymous/JJ
(/(
G3048A-T1016T/NN
)/)
./.
====================
Since/IN
a/DT
non-synonymous/JJ
nucleotide/NN
change/NN
in/IN
the/DT
SCN5A/NN
gene/NN
is/VBZ
likely/JJ
to/TO
induce/VB
a/DT
functional/JJ
change/NN
in/IN
the/DT
sodium/NN
channel/NN
,/,
a/DT
non-synonymous/JJ
substitution/NN
was/VBD
considered/VBN
a/DT
candidate/NN
for/IN
the/DT
variation/NN
associated/VBN
with/IN
this/DT
disorder/NN
./.
====================
In/IN
this/DT
study/NN
,/,
a/DT
non-synonymous/JJ
variation/NN
,/,
C48G-F16L/NN
,/,
was/VBD
not/RB
found/VBN
in/IN
the/DT
normal/JJ
control/JJ
group/NN
but/CC
was/VBD
detected/VBN
only/RB
in/IN
the/DT
patient/NN
group/NN
,/,
suggesting/VBG
that/IN
it/PRP
may/MD
effect/VB
AVB/NN
./.
====================
However/RB
,/,
G298S/NN
[/(
11/CD
]/)
,/,
G514C/NN
[/(
12/CD
]/)
,/,
P1008S/NN
[/(
13/CD
]/)
,/,
G1406R/NN
[/(
14/CD
]/)
,/,
and/CC
D1595N/NN
[/(
11/CD
]/)
,/,
identified/VBD
in/IN
other/JJ
ethnic/JJ
populations/NNS
,/,
were/VBD
not/RB
detected/VBN
,/,
thought/VBN
to/TO
be/VB
due/JJ
to/TO
very/RB
low/JJ
frequency/NN
or/CC
no/DT
variation/NN
in/IN
the/DT
Korean/JJ
population/NN
./.
====================
In/IN
summary/NN
,/,
our/PRP$
data/NNS
may/MD
provide/VB
useful/JJ
information/NN
for/IN
the/DT
identification/NN
of/IN
novel/JJ
variations/NNS
related/JJ
to/TO
AVB/NN
,/,
and/CC
the/DT
novel/JJ
variants/NNS
may/MD
provide/VB
useful/JJ
bio-markers/NNS
to/TO
study/VB
Korean/NN
cardiac/JJ
disease/NN
./.
====================
In/IN
a/DT
future/JJ
study/NN
,/,
we/PRP
will/MD
conduct/VB
a/DT
functional/JJ
analysis/NN
of/IN
the/DT
novel/JJ
variation/NN
(/(
C48G-F16L/NN
)/)
and/CC
propose/VBP
a/DT
mechanism/NN
for/IN
its/PRP$
contribution/NN
to/TO
the/DT
AVB/NN
phenotype/NN
in/IN
patients/NNS
./.
====================
Also/RB
,/,
we/PRP
will/MD
try/NN
to/TO
find/VB
out/IN
genetic/JJ
variation/NN
sites/NNS
in/IN
other/JJ
genes/NNS
that/WDT
might/MD
be/VB
responsible/JJ
for/IN
AVB/NN
./.
====================
Genomic/JJ
location/NN
and/CC
exon/NN
image/NN
of/IN
SCN5A/NN
gene/NN
and/CC
voltage-gated/JJ
Na+/JJ
channel/NN
α/NN
subunit/NN
./.
====================
(/(
A/NN
)/)
The/DT
SCN5A/NN
gene/NN
is/VBZ
located/JJ
on/IN
human/JJ
chromosome/NN
3p21/NN
./.
====================
(/(
B/NN
)/)
Structure/NN
of/IN
SCN5A/NN
gene/NN
:/:
the/DT
SCN5A/NN
gene/NN
consists/VBZ
of/IN
28/CD
exons/NNS
;/:
among/IN
these/DT
,/,
exon/NN
1/CD
is/VBZ
an/DT
untranslated/JJ
region/NN
./.
====================
(/(
C/NN
)/)
The/DT
voltage-gated/JJ
Na+/JJ
channel/NN
α/NN
subunit/NN
consists/VBZ
of/IN
4/CD
homologous/JJ
domains/NNS
(/(
DI-DIV/NN
)/)
,/,
each/DT
containing/VBG
6/CD
transmembrane-spanning/VBG
segments/NNS
(/(
S1-S6/NN
)/)
./.
====================
Agarose/DT
gel/NN
electrophoresis/NN
of/IN
multiplex/JJ
PCR/NN
products/NNS
from/IN
exon/NN
2/CD
to/TO
exon/NN
28/CD
of/IN
the/DT
SCN5A/NN
gene/NN
./.
====================
M/NN
,/,
100/CD
bp/NN
DNA/NN
size/NN
marker/NN
;/:
lane/NN
1-6/CD
,/,
sample/NN
1-6/CD
;/:
lane/NN
7/CD
,/,
negative/JJ
control/NN
./.
====================
Results/NNS
of/IN
DNA/NN
sequencing/NN
analysis/NN
of/IN
SCN5A/NN
gene/NN
,/,
showing/VBG
nucleotide/NN
and/CC
amino/NN
acid/NN
changes/NNS
./.
====================
DNA/NN
sequencing/NN
results/NNS
of/IN
SCN5A/NN
exon/NN
2/CD
(/(
A/DT
,/,
B/NN
)/)
,/,
exon/NN
12/CD
(/(
C/NN
)/)
,/,
exon/NN
17/CD
(/(
D/NN
)/)
,/,
exon/NN
20/CD
(/(
E/NN
)/)
,/,
and/CC
exon/NN
28/CD
(/(
F/NN
)/)
./.
====================
C48G-F16L/NN
(/(
A/NN
)/)
,/,
A1673G-H558R/NN
(/(
C/NN
)/)
,/,
G3048A-T1016T/NN
(/(
D/NN
)/)
,/,
and/CC
G3578A-R1193Q/NN
(/(
E/NN
)/)
are/VBP
all/DT
heterozygous/JJ
nucleotide/NN
changes/NNS
./.
====================
G87A-A29A/NN
(/(
B/NN
)/)
and/CC
T5457C-D1819D/NN
(/(
F/NN
)/)
are/VBP
heterozygous/JJ
or/CC
homozygous/JJ
changes/NNS
that/WDT
are/VBP
causing/VBG
the/DT
synonymous/JJ
nucleotide/NN
change/NN
./.
====================
Multiplex/JJ
PCR/NN
primers/NNS
for/IN
amplification/NN
of/IN
the/DT
coding/VBG
regions/NNS
and/CC
flanking/JJ
intronic/JJ
sites/NNS
of/IN
SCN5A/NN
and/CC
PCR/NN
conditions/NNS
for/IN
each/DT
primer/NN
pair/NN
====================
Genetic/JJ
variations/NNS
and/CC
allele/NN
frequencies/NNS
in/IN
the/DT
SCN5A/NN
gene/NN
of/IN
Korean/JJ
complete/JJ
atrioventricular/JJ
conduction/NN
block/VBP
patients/NNS
(/(
n=113/NN
)/)
and/CC
normal/JJ
controls/NNS
(/(
n=80/CD
)/)
====================
